• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Allergan expands neurological portfolio with $125m Chase Pharmaceuticals buy

November 23, 2016 By Sarah Faulkner

Allergan buys Chase PharmaceuticalsAllergan (NYSE:AGN) said today that it acquired Chase Pharmaceuticals for an upfront payment of $125 million, expanding the Dublin-based company’s neurological portfolio.

Washington, D.C.-based Chase is developing a combination therapy of an acetylcholinesterase inhibitor and a cholinergic blocker in the hopes of improving cognition in patients with Alzheimer’s disease. The acetylcholinesterase inhibitors available on the market are limited to small doses because of the side effects, which include diarrhea, nausea and vomiting.  Chase touted results from phase II clinical trials, where 88% of patients reached the maximum allowable dose without experiencing dose-limiting adverse events.

The company held an end of phase II meeting with the FDA and Allergan said it intends to advance the combination therapy into a phase III registration study next year.

According to the agreement, Allergan will pay additional regulatory and sales milestones payments related to Chase’s lead candidate and other backup compounds.

“Alzheimer’s disease is a neurodegenerative disease that represents a major and growing global public health problem,  for which very few approved treatment options are available, and the societal cost is measured in hundreds of billions of dollars, so the need for improved treatment choices is paramount,” Allergan’s chief R&D officer David Nicholson said in prepared remarks. “This acquisition adds a new Phase 3 ready program for Alzheimer’s disease to our CNS portfolio and builds on our commitment to develop innovative approaches to improve the lives of millions of patients suffering from this devastating illness.”

“We at Chase Pharmaceuticals are passionate about developing and bringing to physicians and their patients profoundly improved Alzheimer’s disease treatments,” Chase president & CEO Douglas Ingram added. ” I am very excited that Allergan has recognized the strong clinical value of our development programs and look forward to seeing Allergan apply its leading clinical development and regulatory expertise to bring these potential treatments forward for patients.”

“We believe our lead candidate, CPC-201, will offer a significant improvement over existing therapy in the symptomatic treatment of Alzheimer’s disease, and will benefit all those suffering from this disease,” Chase co-founder & chief scientific officer Thomas Chase said.

“When determining appropriate treatment for my patients with Alzheimer’s, I am looking for treatments that provide a beneficial effect with the lowest possible side effect profile,” Dr. Jeffrey Cummings, director of the Cleveland Clinic’s Lou Ruvo Center for Brain Health and a former consultant for Chase, explained. “The potential to provide improved cognition without the dose-limiting side effects of currently available [acetylcholinesterase inhibitors]  would be a welcome advance for medical professionals, their patients and caregivers who seek better approaches to manage the symptoms of Alzheimer’s disease.”

Filed Under: Business/Financial News, Featured, Mergers & Acquisitions, Neurological, Pharmaceuticals Tagged With: Allergan, Chase Pharmaceuticals

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS